SNTI (Senti Biosciences Holdings, Inc.) PDUFA Date

Jul 15, 2026

▼ -39.7%on this news· ran to -55% by day 3

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform

Senti Biosciences Holdings, Inc. announced a strategic transaction to enhance its focus on controllable genetic medicines via its Regulator Dial technology. This involves a spin-off of its Gene-Circuit-enabled pipeline, including SENTI-202, to a new company controlled by Celadon. The deal includes contingent value rights for future milestone payments tied to SENTI-202's success.

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

Senti Biosciences Holdings announced a positive outcome from a Type B RMAT meeting with the FDA regarding its CAR-NK cell therapy, SENTI-202, aimed at treating relapsed/refractory acute myeloid leukemia (R/R AML). The company plans to conduct a pivotal multi-center trial based on strong Phase 1 results, including the identification of a donor phenotype that optimizes treatment efficacy. As part of their strategy, Senti Bio will utilize cells from donors with this specific phenotype for future manufacturing of SENTI-202. The therapy has demonstrated noteworthy early clinical outcomes, establishing a promising pathway for registration and potential wider use in AML treatment.

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase Secured strategic financing vehicle for up to $40 million Positive FDA feedback s

Senti Biosciences Holdings reported its financial results for Q1 2026, highlighting the advancement of its SENTI-202 program into a pivotal trial for relapsed refractory acute myeloid leukemia (R R AML). The company secured a strategic financing agreement of up to $40 million and received positive feedback from the FDA that supports the study's design. Additionally, Senti reported a significant reduction in both net loss and operational cash burn compared to the same period last year, as they streamline operations and advance clinical strategies. The SENTI-202 product continues to demonstrate potential with durable responses in ongoing trials.

Apr 14, 2026

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

Senti Biosciences will present its innovative Logic-Gated cell therapies at the AACR Annual Meeting 2026. CEO Timothy Lu will discuss the advancements of the SENTI-202 therapy, which selectively targets cancer cells while protecting healthy ones. The session aims to highlight the potential of Logic Gates in oncology, particularly for relapsed/refractory acute myeloid leukemia.

Apr 1, 2026

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

Senti Biosciences has published new research in Cell Systems showcasing its innovative NOT-gated CAR circuits, which enhance the precision and safety of cell therapies. The study indicates that these circuits can improve the efficacy of immune cells in targeting tumors while sparing healthy tissue. This research supports Senti's ongoing development of its Gene Circuit platform for cancer treatments.

Mar 27, 2026

▼ -10.4%on this newsshared move

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Senti Biosciences reported its financial results for Q4 and full year 2025, highlighting significant progress in its clinical pipeline, particularly with SENTI-202 for relapsed/refractory AML. The company received RMAT designation from the FDA and reported positive preliminary clinical data. However, it also faced a substantial net loss for the year.

Mar 23, 2026

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

Senti Biosciences is set to present clinical and translational data for its SENTI-202 program at the 11th Annual Innate Killer Conference. The Phase I trial focuses on a novel CAR NK cell therapy targeting CD33 and FLT3 in adults with relapsed/refractory acute myeloid leukemia. Presentations will highlight both clinical results and the therapy's unique mechanism of action.

Mar 3, 2026

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

Senti Biosciences, a clinical-stage biotechnology company, announced that CEO Timothy Lu will present at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 9, 2026. The company focuses on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision in targeting cancer cells. A webcast of the presentation will be available on their website.

Feb 24, 2026

▲ +7.1%on this news

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

Senti Biosciences, a clinical-stage biotech firm, will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Timothy Lu will discuss the company's Gene Circuit technology, pipeline advancements, and partnership opportunities. The event will be available via live webcast, emphasizing Senti's commitment to developing innovative therapies for incurable diseases.

Feb 20, 2026

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

Senti Biosciences participated in the Cell & Gene Live event, discussing advancements in cell therapy development. The company highlighted its Gene Circuit platform and its product candidate, SENTI-202, designed to target hematologic malignancies. SENTI-202 has received FDA designations for its potential in treating relapsed/refractory conditions. The event facilitated valuable industry discussions on innovative therapeutic solutions.

Feb 11, 2026

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Senti Biosciences has completed enrollment in its Phase 1 clinical trial for SENTI-202, a CAR NK cell therapy targeting relapsed or refractory acute myeloid leukemia (R/R AML). The trial showed promising results, including durable complete remissions and a favorable safety profile. The company plans to discuss the next steps with the FDA in 2026, aiming for a pivotal study and potential expansion into newly diagnosed and pediatric AML.

Feb 4, 2026

▼ -8.2%on this news

Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

Senti Biosciences has been selected to present at the Healthcare Conference Taipei 2026, where CEO Timothy Lu will discuss the company's Gene Circuit technology. The presentation aims to highlight the company's progress and potential partnerships in cell and gene therapies. The event is expected to attract global investors and strategic partners.

Jan 15, 2026

SNTIFDA Updates

Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

Senti Biosciences participated in a Virtual Investor CEO Connect Segment, where CEO Timothy Lu discussed the FDA's granting of RMAT designation to SENTI-202, a CAR-NK cell therapy. This investigational therapy is aimed at treating relapsed/refractory AML and builds on previous Orphan Drug Designation. Recent clinical trial data from 20 patients was also shared at the ASH Annual Meeting.

Jan 9, 2026

Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

Senti Biosciences, Inc. will participate in the Biotech Showcase 2026, with CEO Dr. Timothy Lu as a panelist. The panel will focus on advancements in cell and gene therapies. The event, scheduled for January 12-14, 2026, in San Francisco, serves as a key networking platform for biotech companies and investors.

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

Senti Bio has announced promising results from its ongoing Phase 1 trial of SENTI-202, a CAR NK cell therapy for relapsed or refractory Acute Myeloid Leukemia (R/R AML). The data presented at the ASH Annual Meeting highlights deep, durable complete remissions and a favorable safety profile. The therapy has received RMAT designation from the FDA, validating its potential to address unmet medical needs in AML treatment.

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

Senti Biosciences has received FDA Regenerative Medicine Advanced Therapy designation for its investigational cell therapy, SENTI-202, aimed at treating relapsed or refractory acute myeloid leukemia (AML). This designation underscores the urgent need for improved therapies in this area and highlights SENTI-202's potential to transform treatment outcomes. The therapy has shown promising clinical results, as presented at the recent ASH Annual Meeting.

Dec 8, 2025

▲ +12.2%on this news· ran to -34% by day 3shared move

Promising results from an ongoing Phase I multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

The ongoing Phase I multicenter study of SENTI-202, a novel CAR NK cell therapy, has shown promising results for adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). This therapy selectively targets CD33 and FLT3, representing a significant advancement in treatment options. The findings were presented at the American Society of Hematology (ASH) Annual Meeting 2025.

Dec 8, 2025

▲ +12.2%on this news· ran to -34% by day 3shared move

Correlative data from an ongoing Phase 1, multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

The ongoing Phase 1 study of SENTI-202, a novel CAR NK cell therapy for Acute Myeloid Leukemia (AML), presents correlative data that aligns with its clinical efficacy. This first-in-class therapy targets CD33 and/or FLT3 while avoiding endomucin. The findings were shared at the American Society of Hematology Annual Meeting 2025.

Dec 4, 2025

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET

Senti Bio will host a conference call on December 9, 2025, to discuss updated clinical results for SENTI-202, a CAR-NK cell therapy targeting hematologic malignancies. The call will feature key executives and a hematologist involved in the study. SENTI-202 aims to selectively eliminate cancer cells while protecting healthy bone marrow.

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

Senti Biosciences reported its third quarter 2025 financial results and announced plans to present clinical data from its Phase 1 SENTI-202 study at the upcoming ASH Annual Meeting. The data will focus on patients with relapsed/refractory acute myeloid leukemia (AML) and aims to demonstrate the efficacy and safety of their Gene Circuit technology. The company is actively expanding patient enrollment and achieving significant milestones in its clinical development.

Nov 3, 2025

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

Senti Bio announced it will present updated clinical results for its SENTI-202 therapy at the ASH Annual Meeting in December 2025. This first-in-class cell therapy targets CD33 and FLT3 in relapsed/refractory acute myeloid leukemia (AML) while protecting healthy cells. The company aims to address the significant unmet need for effective AML treatments.

Oct 16, 2025

▼ -5.6%on this news

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

Senti Biosciences, Inc. announced that CEO Timothy Lu will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The company is focused on developing next-generation cell and gene therapies using its Gene Circuit platform. Management will also hold one-on-one meetings with investors during the event.

Oct 6, 2025

Senti Bio to Present at BioJapan

Senti Biosciences, Inc. will present at BioJapan from October 8-10, 2025, in Yokohama, Japan. CEO Timothy Lu will deliver a presentation on October 9, focusing on the company's Gene Circuit platform for cell and gene therapies. Senti Bio will also engage with investors through one-on-one meetings and has a booth at the event.

Sep 18, 2025

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

Senti Biosciences, Inc. announced that Dr. Kanya Rajangam will present at the MedInvest Biotech & Pharma Conference on September 24, 2025. The presentation will focus on their proprietary Gene Circuit platform, which is aimed at developing advanced cell and gene therapies. Additionally, management will hold one-on-one meetings with investors during the conference.

Sep 2, 2025

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Senti Biosciences, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. CEO Timothy Lu will discuss the company's advancements in cell and gene therapies using their Gene Circuit platform. The event will also include opportunities for in-person meetings with investors. A live video webcast of the presentation will be available.

Aug 14, 2025

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Senti Biosciences, a clinical-stage biotech firm, will present at the Webull Financial Corporate Connect Webinar Series from August 19-21, 2025. CEO Timothy Lu will lead the presentation on their innovative Gene Circuit platform, which aims to develop advanced cell and gene therapies. This event highlights Senti Bio's commitment to addressing incurable diseases.

Aug 12, 2025

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Senti Bio participated in a virtual investor segment discussing its Phase 2 dose selection for SENTI-202, a CAR-NK cell therapy targeting acute myeloid leukemia. Dr. Kanya Rajangam highlighted the therapy's potential as a first-in-class treatment for relapsed/refractory hematologic malignancies. The segment reflects Senti Bio's commitment to developing advanced therapies using its Gene Circuit platform.

Aug 7, 2025

▼ -8.9%on this newsshared move

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

Senti Biosciences reported its Q2 2025 financial results and highlighted advancements in its Phase 1 SENTI-202 study for Acute Myeloid Leukemia (AML). The company has completed dose finding and confirmed the recommended Phase 2 dose, now entering the dose expansion phase. Additionally, Senti Bio received Orphan Drug Designation for SENTI-202 and anticipates releasing more data by the end of the year.

Aug 5, 2025

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Senti Biosciences has established the recommended Phase 2 dose (RP2D) for its investigational therapy SENTI-202 in a Phase 1 study targeting relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The RP2D is set at 1.5 x 10^9 CAR+ NK cells administered in a specific schedule. Preliminary results indicate a favorable safety profile and significant remission rates among patients. The company plans to release further clinical data by year-end.

Jul 22, 2025

Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Senti Biosciences participated in the Virtual Investor 'What’s Your Story' Summer Spotlight On-Demand Conference, where CEO Timothy Lu discussed his commitment to the company and its innovative programs. The on-demand video is available for viewing on the company's website and virtual investor platform. Senti Bio focuses on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform.

Jul 18, 2025

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

Senti Biosciences, Inc. (Nasdaq: SNTI) has appointed Bryan Baum to its Board of Directors, enhancing its leadership team as it develops next-generation cell and gene therapies. Baum, a seasoned entrepreneur with investments in influential companies, brings valuable expertise to Senti Bio. The CEO expressed optimism that Baum's track record will aid in advancing their Gene Circuit programs, which aim to revolutionize cancer treatment. This strategic appointment is seen as a move to optimize the company’s growth and innovation potential.

Jul 17, 2025

Bryan Baum

Bryan Baum is a prominent entrepreneur and investor, known for co-founding K5 Global and investing in major companies like SpaceX and OpenAI. He has successfully exited multiple ventures, including legal tech and mapping software companies. Baum has been recognized for his contributions to technology and serves on the board of the Federal Drug Agents Foundation.

▼ -18%on this news· ran to -28% by day 3

Jun 18, 2025

SNTIFDA Updates

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia Ongoing progress in Ph

Senti Bio has been granted Orphan Drug Designation by the U.S. FDA for SENTI-202, its first-in-class off-the-shelf CAR NK cell therapy. This designation is aimed at treating Acute Myeloid Leukemia (AML), which affects approximately 20,800 newly diagnosed patients annually in the U.S., many of whom face a poor prognosis. The company is currently advancing its Phase 1 clinical trial for SENTI-202, highlighting the therapy's potential to effectively target AML while sparing healthy cells. This milestone reinforces Senti Bio's commitment to developing new treatment options for hematologic malignancies.

May 6, 2025

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual

Senti Bio reported its financial results for the first quarter of 2025 and highlighted positive Phase 1 data from its lead program, SENTI-202. This program demonstrated that 4 out of 7 patients achieved composite complete remission, with responses lasting over 4 to 8 months. The ongoing enrollment in the SENTI-202 trial aims to confirm the recommended Phase 2 dose and further explore the treatment's potential for acute myeloid leukemia (AML) and possibly other solid tumors. Senti Bio continues to expand its pipeline and market efforts, including financial updates and participation in investor engagement activities.

Apr 30, 2025

SENTI-202 CD33 OR FLT3 NOT EMCN Logic-Gated Gene Circuit Components Selectively Target AML while Protecting Human HSC/HPCs from Off-Tumor Toxicity in a Humanized Mouse Model

The article discusses SENTI-202, a gene circuit technology designed to target Acute Myeloid Leukemia (AML) while minimizing toxicity to human hematopoietic stem and progenitor cells. The findings indicate that the logic-gated components of SENTI-202 selectively engage AML cells, showcasing its potential as a therapeutic option. This advancement could significantly enhance treatment safety and efficacy.

Apr 29, 2025

▼ -12.9%on this newsshared move

First-In-Human, Multicenter Study of SENTI-202, a CD33/FLT3 Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Hematologic Malignancies including AML: Correlative Data

The article discusses a first-in-human, multicenter study of SENTI-202, a novel CAR NK cell therapy targeting CD33 and FLT3 in patients with hematologic malignancies, including acute myeloid leukemia (AML). The study aims to evaluate the therapy's effectiveness and safety, providing correlative data to support its potential use in clinical settings. This innovative approach could significantly advance treatment options in this challenging area.

Apr 28, 2025

▼ -27.2%on this newsshared move

snti_conferencecall NASDAQ: SNTI | sentibio.com SENTI-202: Positive Preliminary Results in the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML in Ongoing Phase 1 Trial (SENTI-202-101)

Senti Biosciences reported positive preliminary results from its ongoing Phase 1 trial (SENTI-202-101) for treating relapsed/refractory acute myeloid leukemia (AML). The trial showcased a complete response rate and durability of treatment results. The company highlighted its innovative Logic-Gated cell therapy technology, which aims to selectively target leukemia cells while sparing healthy cells. Furthermore, the success of this trial may lead to a pivotal study and additional developments in their cancer treatment pipeline.

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

Senti Biosciences, Inc. has appointed James B. Trager, Ph.D., to its Scientific Advisory Board, bringing over 25 years of experience in biotechnology and cellular therapies. Dr. Trager's track record includes the development of significant therapeutic candidates and active roles in various biotech firms. His expertise is anticipated to enhance the advancement of Senti Bio's cancer therapies, particularly its promising SENTI-202 program. The company focuses on innovative cell and gene therapies using its Gene Circuit platform.

Mar 20, 2025

Document Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights - Previously reported MRD negative CR in 2 of 3 relapsed refractory AML patients

Senti Bio has announced its financial results for the fourth quarter and full year 2024, highlighting progress in its pipeline, particularly with SENTI-202, which achieved MRD negative complete remissions in 2 of 3 AML patients. The company raised approximately $47.6 million through PIPE financing, providing a solid financial foundation to continue development and operational needs moving forward. Despite a reported net loss of $52.8 million for the year, initial data from their clinical trials show promise for their gene circuit-enabled therapies. Senti Bio remains focused on advancing its innovative treatments in oncology amidst a backdrop of operational adjustments.

Mar 19, 2025

Feng Hsiung

Mr. Feng Hsiung is the Founder and CEO of Acion Partners, an investment advisory firm. He previously served as CEO (Asia) at York Capital, where he established the firm's Asia operations. Hsiung is also involved with the Young Presidents’ Organization and leads Raising Investment Corporation. He holds a degree from Dartmouth College.

Mar 13, 2025

Senti Bio Appoints Feng Hsiung to Board of Directors

Senti Biosciences, Inc. announced the appointment of Feng Hsiung to its Board of Directors, effective March 7, 2025. Hsiung brings extensive experience in investment finance and strategy, which is expected to enrich the company's strategic objectives and potential for long-term growth. Additionally, Senti Bio granted stock options to new employees as part of its 2022 Inducement Equity Plan, indicating ongoing workforce expansion and engagement. The company focuses on developing advanced cell and gene therapies using its Gene Circuit platform, targeting challenging cancer indications.

Feb 25, 2025

Faraz Siddiqui

Mr. Faraz Siddiqui has joined Senti as a key leader in technical operations, bringing over 27 years of experience in the biopharmaceutical industry. His background includes senior roles at IGM Biosciences, Instil Bio, Kite Pharma, and Genentech, where he excelled in manufacturing operations and process development. Siddiqui holds an MBA and a Bachelor of Science in Biochemistry.

Feb 25, 2025

Document Senti Bio Strengthens Leadership Team with Strategic Hires - Jay Cross, proven financial leader, appointed as CFO to drive strategic growth - - Faraz Siddiqui, expert in manufacturing operations, j

Senti Bio has expanded its leadership team by appointing Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations. Cross, who will begin on March 3, 2025, is expected to enhance the financial strategy and growth of the company, while Siddiqui, who joined in January 2025, will oversee the optimization of the manufacturing process. The appointments reflect the company’s intent to strengthen its clinical development capabilities and support its proprietary Gene Circuit platform, which focuses on innovative cell and gene therapies.

Feb 25, 2025

Senti Bio Strengthens Leadership Team with Strategic Hires

Senti Biosciences, Inc. announced the appointment of Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations, expanding its senior leadership team. Cross will focus on financial strategy, while Siddiqui will oversee manufacturing processes. Both leaders bring extensive experience that is expected to strengthen the company's position in developing next-generation cell and gene therapies. This strategic hiring comes as Senti Bio seeks to advance its clinical pipeline, especially with its lead therapeutic candidates demonstrated effective initial results in clinical trials.

Jan 7, 2025

Donald Tang

Donald Tang is the Managing Partner of Celadon Partners, a private equity firm he founded in 2018. He has a notable history with D.E. Shaw & Co., where he served as CEO for the Asia-Pacific region. Tang also holds positions on the Board of Directors for Vicarious Surgical and has been involved with various prestigious advisory councils.

Jan 6, 2025

▲ +5.3%on this newsshared move

Senti Bio Announces Additional $11.5 Million of Financing - Approximately $10 million additional investment in private placement equity financing - - $1.5 million from CIRM grant first announced in June 2024 - - Cash run

Senti Bio has announced an additional financing of approximately $11.5 million, including $10 million from a private placement and $1.5 million from a CIRM grant. This funding extends the company's cash runway into 2026 and enhances the financial resources available for its continued development of the SENTI-202 program and manufacturing ramp-up. Overall, the total raised in the PIPE financing round is now $47.6 million, indicating strong investor interest. Senti Bio is focused on developing advanced cell and gene therapies using its unique Gene Circuit platform.

Dec 16, 2024

▼ -8.3%on this news· ran to -29% by day 3

Document Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics - Dose-finding clinical trial in China designed to evaluate

Senti Bio has announced the dosing of the first patient in its clinical trial for SN301A, a CAR-NK cell therapy targeting hepatocellular carcinoma (HCC), in partnership with Celest Therapeutics in China. This trial aims to evaluate the safety and preliminary efficacy of SN301A in patients with advanced GPC3-expressing HCC. The partnership with Celest encompasses clinical development, operations, and manufacturing, aiming to address a considerable health threat given that over 40% of global HCC cases occur in China. Additionally, Senti Bio retains rights for development and commercialization of SENTI-301A outside of China and certain territories.

Dec 3, 2024

▼ -28.6%on this news· ran to -45% by day 3

SENTI-202 Initial Clinical Data December 2024 Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our") within the meaning of the Private

Senti Biosciences, Inc. has provided updates regarding its investigational product SENTI-202, a potential NK cell therapy for acute myeloid leukemia (AML). Initial clinical data indicates promising efficacy, with some patients achieving complete remission. However, the company also highlights risks related to ongoing clinical trials and external economic factors that may impact development. Financing has been secured to further pursue SENTI-202's clinical development milestones, with initial data expected by year-end 2024.

Dec 2, 2024

▲ +363%on this newsshared move

Fran Schulz

Fran Schulz has been a board member since 2024, bringing over 35 years of experience from Ernst & Young's Life Sciences Practice. She has played a pivotal role in corporate deals and has raised over $15 billion through various transactions. Currently, she serves on the boards of EDAP TMS SA and Menlo College.

Dec 2, 2024

▲ +363%on this newsshared move

Senti Bio Appoints Fran Schulz to Board of Directors - Biotechnology industry executive with a proven track record of advising management teams on corporate and financial strategy for more than 30 years

Senti Biosciences, Inc. has announced the appointment of Fran Schulz to its Board of Directors, welcoming her significant experience in biotechnology and financial strategy. Schulz has over 30 years in roles that support corporate growth and innovation, particularly in life sciences. Her expertise is anticipated to enhance Senti Bio's strategic direction as the company progresses with its clinical programs and Gene Circuit platform. Concurrently, Dr. Omid Farokhzad will depart from the Board, thanking him for his service.

Dec 2, 2024

▲ +363%on this newsshared move

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancie

Senti Bio announced positive results from its Phase 1 clinical trial of SENTI-202, a CAR-NK cell therapy targeting relapsed/refractory hematologic malignancies like AML. Two out of three treated patients achieved complete remission, confirmed by bone marrow biopsy, and both were MRD negative. The safety profile of SENTI-202 was generally well-tolerated, with planned dose escalation continuing. Further data on response and durability is expected in 2025.

Nov 14, 2024

Document Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights - Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed refractory he

Senti Bio announced its third quarter 2024 results, showcasing ongoing enrollment in its Phase 1 clinical trial for SENTI-202, targeting relapsed refractory hematologic malignancies, with initial data expected by year-end. The company reported a notable net loss of $28.9 million for the quarter and highlighted financial support from the California Institute for Regenerative Medicine. Looking ahead, Senti Bio anticipates sharing additional data in 2025, reflecting continued progress in their oncology program.

Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits

The article discusses advancements in natural killer (NK) cell therapies for oncology, emphasizing the development of off-the-shelf solutions enhanced by logic-gated gene circuits. These innovations aim to improve the effectiveness of cancer treatments by providing readily available therapeutic options. The research highlights the collaborative efforts of various scientists in this promising field.

Aug 13, 2024

▲ +10.7%on this news· ran to +30% by day 3shared move

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Senti Bio reported its second quarter 2024 results, highlighting progress in its clinical trials and corporate developments. Notably, the company has commenced dosing in the Phase 1 trial of SENTI-202 for relapsed/refractory hematologic malignancies and has received an $8 million grant from CIRM for its clinical development. Additionally, Senti Bio is preparing to initiate a pilot trial of SENTI-301A for hepatocellular carcinoma in collaboration with Celest Therapeutics in China. Despite these advancements, the company reported a net loss of $11.2 million for the quarter.

Aug 13, 2024

▲ +10.7%on this news· ran to +30% by day 3shared move

Document Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights - Dose Finding Ongoing in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed Refr

Senti Bio announced its second-quarter 2024 results, highlighting ongoing dosing in its Phase 1 trial of SENTI-202 for relapsed refractory AML. The company has also commenced an $8 million grant from CIRM to support this development. Furthermore, a pilot trial for SENTI-301A in hepatocellular carcinoma is expected to start in China by Q4 2024. However, Senti Bio reported a net loss of $11.2 million during the quarter and had to implement a reverse stock split to meet Nasdaq requirements.

Jul 16, 2024

Senti Bio Announces Reverse Stock Split

Senti Biosciences, Inc. announced a 1-for-10 reverse stock split of its common stock to take effect on July 17, 2024. This strategy is aimed at increasing the stock price after non-compliance with Nasdaq's minimum bid requirements. As a biotechnology company developing advanced cell and gene therapies, Senti Bio believes this move will help restore its compliance with Nasdaq listings. The company has a proprietary technology platform aimed at enhanced therapeutic efficacy but is currently under stock price pressure.

Brian Garrison, Ph.D.

Dr. Brian Garrison has been with Senti Bio since 2016, utilizing his extensive experience in cell and gene therapy to advance the company's Gene Circuit technologies. He currently oversees the Discovery Research and Translational Science Teams. Garrison holds a B.S. in Microbiology and a Ph.D. in human gene therapy, with a strong background in stem cell biology and genome editing.

May 15, 2024

Iterative Engineering of Polarization-State Responsive Synthetic Promoters for Autonomous Control of Macrophage Polarization Logic

The article discusses the presentation of research on synthetic promoters designed for controlling macrophage polarization at the ASGCT Annual Meeting. The study highlights an innovative engineering approach that could enhance the understanding and manipulation of immune responses. The collaborative effort involves multiple researchers, indicating a strong interest in advancing synthetic biology applications.

May 15, 2024

Engineered IMiD Regulated Synthetic Transcriptional Switch for Controlled and Dose-Responsive Expression of Therapeutic Payload within FDA-Approved Drug Doses

The article discusses a presentation at the ASGCT Annual Meeting regarding an engineered IMiD regulated synthetic transcriptional switch. This technology aims to enable controlled and dose-responsive expression of therapeutic payloads within FDA-approved drug doses. The details of the research and its implications were presented by a team of researchers.

May 15, 2024

Discovery of Novel CARs for Solid Tumors Using Senti REVEAL™

Senti Biosciences has announced the discovery of novel CARs aimed at treating solid tumors using their Gene Circuit Technology Platform. This innovative approach may enhance the effectiveness of cancer therapies. The findings were presented at the ASGCT Annual Meeting, highlighting the company's commitment to advancing cancer treatment options.

Document Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights - First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia ("AML")

Senti Bio has announced its first quarter 2024 results, highlighting the planned initiation of patient dosing for SENTI-202, a CAR-NK therapy for acute myeloid leukemia, scheduled for Q2 2024. Additionally, the company reported positive preclinical data supporting the efficacy of its therapies and acknowledged a strategic collaboration with Celest for the development of SENTI-301A in hepatocellular carcinoma. Financial results revealed a net loss of $12.1 million for the quarter, while R&D expenses have risen, prompting scrutiny of the company's financial health amidst ongoing clinical developments.

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

Senti Biosciences reported its financial results for the first quarter of 2024 and announced progress in its clinical trials. The company is set to begin patient dosing in its Phase 1 trial of SENTI-202 for acute myeloid leukemia in Q2 2024. Additionally, SENTI-301A is also on track for a pilot trial in China through a partnership with Celest Therapeutics. Despite these advancements, the company reported a net loss of $12.1 million for the quarter, raising concerns about ongoing financial sustainability.

Apr 8, 2024

Preclinical data supporting the Phase 1 trial design of SENTI-202, a next generation allogeneic logic-gated selective CAR-NK cell therapy, engineered to overcome key limitations of first generation cell therapies in AML

The article discusses preclinical data supporting the Phase 1 trial design of SENTI-202, a next-generation allogeneic logic-gated selective CAR-NK cell therapy. This innovative therapy aims to overcome key limitations associated with first-generation cell therapies, particularly in the treatment of acute myeloid leukemia (AML). The research was presented at the AACR Annual Meeting.

Document Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights - IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S

Senti Biosciences reported its fourth quarter and full year 2023 financial results, highlighting significant achievements including the IND clearance for its investigational cell therapy SENTI-202 for acute myeloid leukemia (AML). The company anticipates dosing its first patient in the second quarter of 2024 and expects to generate initial efficacy data by the end of 2024. Despite these milestones, Senti Bio faced an increased net loss for the year amounting to $71.1 million. The company has structured its operations to focus on advancing its clinical programs with expectations to extend its cash runway into the first quarter of 2025.

Jan 5, 2024

▼ -6.2%on this news· ran to -23% by day 3

Document Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program - Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partner

Senti Bio announced strategic steps to prioritize investment in its lead clinical programs, SENTI-202 and SENTI-301A, by significantly reducing its workforce by 37%. This decision is aimed at supporting the clinical development of SENTI-202, which has received FDA clearance for its IND application. The company anticipates initial efficacy data from the Phase 1 trial of SENTI-202 by the end of 2024 and expects to extend its cash runway into the first quarter of 2025. Despite these advancements, the workforce reduction raises concerns about the impact on employee morale and ongoing research initiatives.

Dec 20, 2023

SNTIFDA Updates

Document Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - First patient in Phase 1 c

Senti Bio has received FDA clearance for its IND application for SENTI-202, a groundbreaking CAR-NK cell therapy aimed at treating relapsed or refractory hematologic malignancies, including acute myeloid leukemia. The company is set to begin a Phase 1 clinical trial in 2024, with initial efficacy data expected by the end of the year. The innovative therapy utilizes a Logic Gated system to differentiate between cancerous and healthy cells, potentially improving treatment outcomes for patients with limited options. This development marks a crucial step for Senti Bio as it advances its clinical-stage offerings.

Dec 13, 2023

▲ +7.1%on this news· ran to +17% by day 3

Rob Cutler, J.D.

Rob Cutler has been appointed as the Senior Vice President and Head of Legal Affairs at Synthetech, effective November 2024. He brings a wealth of experience from his previous roles, including Chief Legal Officer at Telesis Bio and General Counsel at Synthetic Genomics. His background in biotech law and business development positions him well for this role.

Dec 12, 2023

▼ -12.5%on this newsshared move

Thomas Chung

Mr. Thomas Chung has joined Senti Bio, bringing extensive experience in investing and operations across various industries. With a background in life sciences and healthcare, he has managed significant investments and portfolio companies. Chung's career includes roles at UBS Investment Bank and Health Evolution Partners, showcasing his expertise in driving value creation.

Dec 11, 2023

▼ -12.5%on this newsshared move

Calibrated Release IL15-Expressing Bivalent CD33 and/or FLT3 Logic Gated Gene Circuit CAR-NK Cell Therapy (from SENTI-202 gene circuit) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

The article discusses a new CAR-NK cell therapy utilizing a calibrated release IL15-expressing bivalent CD33 and/or FLT3 gene circuit. This therapy is designed for acute myeloid leukemia (AML) models that are resistant to venetoclax. The research was presented at the ASH Annual Meeting, highlighting its potential to improve treatment outcomes in challenging patient populations.

Dec 9, 2023

▼ -7%on this news· ran to -19% by day 1shared move

Michael Varney, Ph.D.

Dr. Michael Varney is a prominent figure in biotechnology, currently serving as the Chairman of R&D at Erasca. With a rich history in drug discovery, he has played key roles in developing several approved cancer therapies. His expertise stems from his tenure at Genentech and other leading biotech firms, where he has significantly advanced cancer treatment options.

Dec 9, 2023

▼ -7%on this news· ran to -19% by day 1shared move

Amy Alford

Mrs. Amy Alford has been leading Senti's R&D and clinical operations since 2022, bringing over 20 years of experience in clinical operations. Her background includes roles at Kronos Bio, Peloton Therapeutics, and Reata Pharmaceuticals, as well as consulting on clinical development. Alford has been part of teams for several FDA-approved products.

Dec 8, 2023

James B. Trager, Ph.D.

Dr. James B. Trager, Ph.D., joins Senti Bio as a biotechnology leader with extensive experience in cellular therapies for cancer. With over 25 years in the field, he has held significant roles, including Chief Scientific Officer at Nkarta Therapeutics and Vice President at Dendreon Pharmaceuticals. His contributions include nearly 50 publications and patents, showcasing his impact on the industry.

Dec 7, 2023

Robin G. Taylor, M.B.A., Ph.D.

Dr. Robin G. Taylor is a seasoned biopharma consultant with over 20 years of experience in oncology drug development and commercialization. He previously served as Chief Commercial Officer at Seagen, where he oversaw the launches of PADCEV and Tukysa. Taylor has held leadership roles at Genentech and AstraZeneca, contributing to the success of various oncology therapies. He holds a PhD in Molecular and Medical Genetics and an MBA.

Dec 7, 2023

Ed Mathers

Ed Mathers has been a board member since 2016 and is a General Partner at New Enterprise Associates. He has a strong background in healthcare investments and previously held leadership roles at MedImmune. Mathers also serves on the boards of multiple biopharma companies, showcasing his extensive industry involvement.

Dec 5, 2023

▼ -8.2%on this newsshared move

Michael Kalos, Ph.D.

Dr. Michael Kalos is a prominent figure in T cell therapy and immuno-oncology, with over 25 years of experience. He has held significant roles at major pharmaceutical companies and has a strong academic background, including founding a key laboratory at the University of Pennsylvania. His contributions include numerous publications and patents in cell therapy and vaccines.

Dec 5, 2023

Brenda Cooperstone, M.D.

Dr. Brenda Cooperstone has been a board member since 2019 and has a strong background in rare disease development at Pfizer. She previously worked at Wyeth Pharmaceuticals and has held various leadership roles, including Senior Vice President. Dr. Cooperstone's educational credentials include an M.D. from McGill University and specialized training in pediatrics and nephrology.

Dec 5, 2023

Kanya Rajangam, M.D., Ph.D.

Dr. Kanya Rajangam, M.D., Ph.D., is leading research and clinical development at Senti. She has held significant roles in biotech, including CMO at Nkarta Therapeutics and Atara Biotherapeutics, focusing on CAR-NK and T-cell therapies. Her experience includes contributions to the approval of key oncology products and serving on the board of Turnstone Biologics.

Dec 3, 2023

Jay Cross

Jay Cross is the Chief Financial Officer of Senti Bio, responsible for financial strategy and investor relations. He has a notable background, having previously served as CFO at Sonnet BioTherapeutics and worked on Wall Street for 20 years. His expertise in healthcare investment banking and finance supports Senti Bio's growth.

Dec 3, 2023

James Collins, Ph.D

Dr. James Collins, a prominent figure in synthetic biology, holds multiple prestigious positions at MIT and Harvard. He has been recognized with numerous awards, including the Dickson Prize in Medicine. As a co-founder of several biotech companies, he continues to influence the field significantly.

Dec 2, 2023

Michael Andreeff, M.D., Ph. D.

Dr. Michael Andreeff is a distinguished Professor of Medicine at the University of Texas MD Anderson Cancer Center, where he holds the Paul and Mary Haas Chair in Genetics. He has a notable focus on drug resistance in hematopoietic malignancies, particularly acute myelogenous leukemia (AML), and has contributed to the development of several new therapeutic agents. His extensive training includes degrees from the University of Heidelberg and faculty roles at Memorial Sloan-Kettering Cancer Center.

Dec 1, 2023

▲ +7.3%on this newsshared move

Timothy Lu, M.D., Ph.D.

Dr. Timothy Lu has been the CEO of Senti Bio since its founding in 2016. He is a former tenured faculty member at MIT and has co-founded several biotech companies. Dr. Lu holds an M.D. from Harvard and a Ph.D. from MIT, and he has received multiple awards for his contributions to synthetic biology.

Nov 13, 2023

▼ -16.3%on this news· ran to -32% by day 1

Document Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates - IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 - - Establish

Senti Biosciences has reported its third quarter 2023 results, highlighting progress in its pipeline, including upcoming IND clearance for SENTI-202 and a partnership with Celest Therapeutics for the clinical development of SENTI-301A in China. The company’s financials show a net loss of $14.9 million but expect operational funding through the GeneFab transaction. Senti Bio aims to initiate a Phase 1 trial for SENTI-202 early in 2024.

Nov 6, 2023

Document Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China - Celest to lead clinical development with technical support from Senti Bio

Senti Bio has announced a strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A, aimed at treating solid tumors in China. Under the agreement, Celest will lead clinical operations while receiving technical support from Senti Bio, with the first patient expected to be enrolled in early 2024. Senti Bio stands to gain up to $156 million in milestone payments, along with potential royalties. This partnership aims to address the unmet medical needs in treating advanced hepatocellular carcinoma (HCC) in the region.

Smart sensor promoters drive state-specific gene circuits to convert immunosuppressive macrophages into an anti-tumor phenotype

The article discusses a presentation at the SITC Annual Meeting regarding the use of smart sensor promoters to drive state-specific gene circuits. This approach aims to convert immunosuppressive macrophages into an anti-tumor phenotype, potentially enhancing cancer therapies. The research highlights a novel method that could lead to improved outcomes in cancer treatment.

Small-molecule regulated safety switch for improved safety of CAR cell therapies in the brain

The article discusses a novel small-molecule regulated safety switch designed to enhance the safety of CAR cell therapies specifically for brain applications. This innovation was presented at the SITC Annual Meeting by a team of researchers, highlighting its potential to mitigate risks associated with CAR therapies. The development aims to address safety concerns in the administration of these therapies.

NOT gate gene circuits expand the range of tumor-associated antigens addressable by CAR-NK and -T cell therapies

The article discusses advancements in NOT gate gene circuits that broaden the spectrum of tumor-associated antigens targeted by CAR-NK and CAR-T cell therapies. This innovative approach was highlighted at the SITC Annual Meeting, showcasing its potential to enhance cancer treatment efficacy. The research involves contributions from multiple experts in the field.

High-throughput discovery of constitutive promoters to drive strong expression of next-generation gene circuits in CAR-NK and -T cells

The article discusses the high-throughput discovery of constitutive promoters aimed at enhancing gene circuit technology for CAR-NK and -T cells. This advancement is expected to drive strong expression of next-generation gene circuits, potentially improving treatment options for conditions like Acute Myeloid Leukemia. The research highlights the innovative approach taken by the team.

Aug 11, 2023

Document Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates - GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 - - IND for SENTI-202, pote

Senti Biosciences announced its second quarter 2023 financial results and provided updates on its pipeline, highlighting the establishment of GeneFab, a clinical manufacturing partner, which extends its cash runway into Q4 2024. The company is on track to file an Investigational New Drug application for SENTI-202, a CAR-NK therapy targeting AML, in the second half of 2023. However, despite these advancements, Senti Bio reported a net loss of $18.7 million, showcasing continued financial strains.

Aug 10, 2023

Document Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners - Celadon Partners to acquire Se

Senti Bio has successfully closed a transaction with Celadon Partners that involves the establishment of GeneFab, an independent contract manufacturing business focused on cell and gene therapies. The agreement allows Senti Bio to leverage its chemistry, manufacturing, and controls (CMC) capabilities while receiving approximately $38 million in cash and an additional $8 million in manufacturing credit. This partnership is anticipated to bolster Senti Bio's oncology programs and ensure seamless technology transfer for clinical manufacturing. Dr. Philip Lee is transitioning from CTO of Senti Bio to CEO of GeneFab, marking a significant restructuring for both organizations.

May 9, 2023

Document Senti Bio Announces First Quarter 2023 Results and Pipeline Updates - New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy remains on track

Senti Biosciences reported positive developments in their pipeline and Q1 2023 financial results. The company is moving forward with the IND application for its SENTI-202 CAR-NK cell therapy, which targets hematologic malignancies. In addition, upcoming presentations at ASGCT will highlight collaborative preclinical data supporting Senti's Gene Circuit platform. Despite a reported net loss, Senti maintains a solid cash runway through early 2024.

Mar 22, 2023

Document Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights - SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 20

Senti Biosciences reported its fourth quarter and full year 2022 financial results, highlighting progress in its oncology candidates, especially SENTI-202. The company plans to submit an Investigational New Drug (IND) application for SENTI-202 in the second half of 2023, which targets hematologic malignancies such as AML and MDS. Additionally, Senti Bio maintains strong financial health with $98.6 million in cash to fund operations through at least 1Q 2024 despite reporting a net loss of $58.2 million for the year. The company continues to advance its Gene Circuit platform and has partnerships aimed at enhancing its cell and gene therapy capabilities.

Jan 27, 2023

Document Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies Updates Cash Runway Guidance - R D focus is on lead oncology candidate SENTI-202 for the treatment of AML and othe

Senti Bio has announced a strategic realignment of its pipeline, prioritizing its lead oncology candidates SENTI-202 and SENTI-401, while extending its cash runway guidance through at least the first quarter of 2024. The company is on track to file an IND application for SENTI-202, aimed at treating acute myeloid leukemia (AML) and related conditions. Additionally, Senti Bio continues to explore partnerships for the clinical development of SENTI-301A targeting hepatocellular carcinoma. The focus on Logic Gated cell therapies signifies the company's commitment to advancing its innovative Gene Circuit technology.

Dec 11, 2022

▼ -9%on this news· ran to -28% by day 1

Document Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event - ASH poster presentation summarizes preclinical data from

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event - ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logi

Document Senti Bio Reports Third Quarter Financial Results and Pipeline Updates - SENTI-202 on track for IND filing in 2023 clinical plans for SENTI-202 expand beyond AML to CD33 and or FLT3 expressing hema

Senti Bio Reports Third Quarter Financial Results and Pipeline Updates - SENTI-202 on track for IND filing in 2023 clinical plans for SENTI-202 expand beyond AML to CD33 and or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for progra

Aug 15, 2022

Document Senti Bio Reports Second Quarter Financial Results and Business Updates - Lead development candidate selected from SENTI-202 program on track for IND filing in 2023 - - Expect to present CAR-NK cel

Senti Bio Reports Second Quarter Financial Results and Business Updates - Lead development candidate selected from SENTI-202 program on track for IND filing in 2023 - - Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 - - Cash posit

SENTI BIOSCIENCES, INC. INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Condensed Consolidated Financial Statements: Condensed Consolidated Balance Sheets F-2 Condensed Consolidated Statements of Operations and

SENTI BIOSCIENCES, INC. INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Condensed Consolidated Financial Statements: Condensed Consolidated Balance Sheets F-2 Condensed Consolidated Statements of Operations and Comprehensive Loss F-3 Condensed Consolidate

Jun 9, 2022

Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits - Business combination with Dynamics Special Purpose Corp. completed today; gross pr

Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits - Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total ap

May 25, 2022

Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development Officer - Cell therapy and oncology drug development expert aims to lead Senti Bio s novel off-the-shelf CAR-NK cell oncology

Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development - Cell therapy and oncology drug development expert aims to lead Senti Bio s novel off-the-shelf CAR-NK cell oncology programs into and through clinical development - SOUTH SAN FRANCIS

May 24, 2022

Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS) - Leaps by Bayer led Series B investment in Senti Bio in 2021; Ad

Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS) - Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed cap

Dec 20, 2021

to the Company s Current Report on Form 8-K filed with the SEC on

Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies - Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide mo

Dec 20, 2021

Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies

- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity (“PIPE”) financing and from non-redemptio

Dec 13, 2021

Senti Bio Highlights Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting

- Preclinical data demonstrates complete functionality of SENTI-202 OR+NOT Logic Gated gene circuits for the elimination of AML cancer cells while sparing healthy stem cells - - Presentation to be featured in virtual ASH Poster Walk intended to highlight recent NK cell advances

Aug 17, 2021

Senti Bio Adds Prominent Scientific and Industry Leaders to its Scientific Advisory Board

- Members include world-leading experts in fields of immunotherapy drug discovery and development and commercial oncology therapeutics - - Dr. James Collins, a founder of the field of synthetic biology, appointed SAB Chairperson - SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLO

May 28, 2021

DYNAMICS SPECIAL PURPOSE CORP. INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOU

DYNAMICS SPECIAL PURPOSE CORP. INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and Board of Directo

May 25, 2021